耐多药肺结核合并 HIV 感染患者中，利福平抗结核治疗时 CYP2B6 516TT 基因型者出现依非韦伦血药浓度升高的矛盾现象。
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
机构信息
The Miriam Hospital, Providence, Rhode Island 02906, USA.
出版信息
AIDS. 2011 Jan 28;25(3):388-90. doi: 10.1097/QAD.0b013e3283427e05.
Abstract
Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on rifampin-containing therapy (n = 18), we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G→T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype.
摘要
在利福平含结核病（TB）治疗期间，一些个体的依非韦伦血浆浓度升高，与利福平预期的诱导作用相反。在未接受（n = 38）和接受利福平含治疗的 HIV 感染患者中（n = 18），我们检验了药物-基因相互作用可能解释这种高度可变的药物相互作用的假设。双向方差分析显示 CYP2B6 516G→T 多态性与利福平含治疗之间存在显著相互作用，表明可能需要根据患者的基因型来个体化调整依非韦伦剂量。
相似文献
1
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
AIDS. 2011 Jan 28;25(3):388-90. doi: 10.1097/QAD.0b013e3283427e05.
2
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Antimicrob Agents Chemother. 2009 Mar;53(3):863-8. doi: 10.1128/AAC.00899-08. Epub 2009 Jan 5.
3
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12.
4
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Pharmacogenomics. 2014 Aug;15(11):1423-35. doi: 10.2217/pgs.14.73.
5
Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.
6
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Clin Pharmacol Ther. 2011 Sep;90(3):406-13. doi: 10.1038/clpt.2011.129. Epub 2011 Aug 3.
7
High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
J Antimicrob Chemother. 2019 Jan 1;74(1):135-138. doi: 10.1093/jac/dky379.
8
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Pharmacogenet Genomics. 2023 Aug 1;33(6):126-135. doi: 10.1097/FPC.0000000000000501. Epub 2023 Jun 12.
9
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
Antiviral Res. 2014 Feb;102:44-53. doi: 10.1016/j.antiviral.2013.11.011. Epub 2013 Dec 5.
10
Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
J Clin Pharmacol. 2016 Dec;56(12):1538-1549. doi: 10.1002/jcph.756. Epub 2016 May 29.
引用本文的文献
1
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Int J Mol Sci. 2023 Feb 8;24(4):3383. doi: 10.3390/ijms24043383.
2
A review of clinical pharmacogenetics Studies in African populations.
Per Med. 2020 Mar;17(2):155-170. doi: 10.2217/pme-2019-0110. Epub 2020 Mar 3.
3
Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.
Front Pharmacol. 2020 Feb 7;11:26. doi: 10.3389/fphar.2020.00026. eCollection 2020.
4
Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00839-19. Print 2019 Oct.
5
Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.
Tuberculosis (Edinb). 2018 Dec;113:153-162. doi: 10.1016/j.tube.2018.09.009. Epub 2018 Oct 1.
6
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.
Sci Rep. 2018 Nov 5;8(1):16316. doi: 10.1038/s41598-018-34674-3.
7
Combination of Tenofovir and Emtricitabine with Efavirenz Does Not Moderate Inhibitory Effect of Efavirenz on Mitochondrial Function and Cholesterol Biosynthesis in Human T Lymphoblastoid Cell Line.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00691-18. Print 2018 Sep.
8
Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.
Lancet Infect Dis. 2018 Mar;18(3):e64-e75. doi: 10.1016/S1473-3099(17)30623-0. Epub 2017 Oct 27.
9
Gynaecomastia in two men on stable antiretroviral therapy who commenced treatment for tuberculosis.
Malawi Med J. 2016 Dec;28(4):185-187. doi: 10.4314/mmj.v28i4.8.
10
Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.
Pharmacogenet Genomics. 2017 Mar;27(3):101-111. doi: 10.1097/FPC.0000000000000263.
本文引用的文献
1
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
Drug Metab Dispos. 2010 Jul;38(7):1218-29. doi: 10.1124/dmd.109.031393. Epub 2010 Mar 24.
2
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
AIDS. 2009 Oct 23;23(16):2101-6. doi: 10.1097/QAD.0b013e3283319908.
3
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
Drug Metab Dispos. 2009 Sep;37(9):1793-6. doi: 10.1124/dmd.109.027706. Epub 2009 Jun 1.
4
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Br J Clin Pharmacol. 2009 Apr;67(4):427-36. doi: 10.1111/j.1365-2125.2009.03368.x.
5
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.
AIDS. 2009 Mar 27;23(6):742-4. doi: 10.1097/QAD.0b013e32832914a3.
6
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
Pharmacogenet Genomics. 2009 Apr;19(4):300-9. doi: 10.1097/FPC.0b013e328328d577.
7
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43. doi: 10.1097/QAI.0b013e31819c33a3.
8
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
Curr HIV Res. 2007 May;5(3):349-53. doi: 10.2174/157016207780636588.
9
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
J Antimicrob Chemother. 2006 Dec;58(6):1299-302. doi: 10.1093/jac/dkl399. Epub 2006 Oct 10.
10
Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring.
Ther Drug Monit. 2006 Aug;28(4):517-25. doi: 10.1097/00007691-200608000-00006.
Zotero 插件